Finance
Beta
search
Search or ask
settings
Theme
mobile
Device default
✓
dark_mode
Dark theme
light_mode
Light theme
Search labs
feedback
Send feedback
Sign in
Lists
playlist_add
New
DARE
Research
DARE:NASDAQ
check_indeterminate_small
Dare Bioscience Inc
$2.11
arrow_upward
+6.57%
(
+0.13
) 1D
$2.05
arrow_downward
-2.84%
(
-0.060
)
bedtime
After hours
Closed: Jun 16, 4:00:01 PM GMT-4 · USD
area_chart
Area
stacked_line_chart
Compare
search
close
All symbols
monitoring
Indicators
No data
1D
5D
1M
6M
YTD
1Y
5Y
MAX
Symbol
Price
Change
% Change
Overview
Earnings
Financials
Holdings
insights_auto
Generating top insights for DARE...
Open
$2.01
High
$2.15
Low
$1.98
Mkt. cap
31.61M
Avg. vol.
624.13K
Volume
0.00
52-wk high
$9.19
52-wk low
$1.27
EPS
-$1.04
Beta
1.07
Shares outstanding
14.98M
No. of employees
21
Open
$2.01
High
$2.15
Low
$1.98
Mkt. cap
31.61M
Avg. vol.
624.13K
Volume
0.00
52-wk high
$9.19
52-wk low
$1.27
EPS
-$1.04
Beta
1.07
Shares outstanding
14.98M
No. of employees
21
Analyst outlook
Analyst Ratings
Based on 2 analysts giving stock ratings to DARE in the past 3 months
Buy
Buy
2
Hold
0
Sell
0
12 month forecast
Based on 2 Wall Street analysts offering 12 month price targets for DARE in the last 3 months.
Highest
Current
$2.11
$12.00
(
+468.72%
)
Average
$10.00
(
+373.93%
)
Lowest
$8.00
(
+279.15%
)
Related stocks
FEMY
Femasys Inc
$3.84
-3.52%
arrow_downward
SERA
Sera Prognostics Inc
$1.86
+1.09%
arrow_upward
OGN
Organon & Co
$13.42
-0.15%
arrow_downward
TXMD
TherapeuticsMD Inc
$2.29
+0.44%
arrow_upward
News stories
From sources across the web
Newsline
·
5 days ago
DARE Q1 2026 Earnings: Narrower-than-expected loss boosts shares 2.0% - Gross Profit Margin
Newsline
·
2 weeks ago
DARE Q1 2026 Earnings: Narrower-than-expected loss surprises, but stock dips on absent revenue
About Dare Bioscience Inc
CEO
Sabrina Martucci Johnson
Employees
21
Founded
2005
Headquarters
San Diego, California, United States
Sector
Pharmaceutical industry
Website
darebioscience.com
Previous reports
All values in USD
Loading Previous Earnings...
Income statement
Balance sheet
Cash flow
Income statement
Revenue
Net income
calendar_month
Quarterly
Quarterly
Annual
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-21.17K
2.26K
1.02M
152.46K
Cost of goods sold
-
1.18M
-4.61M
902.79K
Cost of revenue
-
1.18M
-4.61M
902.79K
Research and development expenses
1.43M
-
5.52M
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2.38M
2.50M
1.58M
2.25M
Operating expense
3.81M
2.50M
7.10M
2.25M
Total operating expenses
3.81M
3.67M
2.49M
3.15M
Operating income
-3.83M
-3.67M
-1.47M
-3.00M
Other non operating income
-188.68K
109.38K
29.55K
-991.00
EBT including unusual items
-4.02M
-3.56M
-1.44M
-3.00M
EBT excluding unusual items
-4.02M
-3.56M
-1.44M
-3.00M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-4.02M
-3.56M
-1.44M
-3.00M
Net profit margin
18,970.73%
-157,505.13%
-140.84%
-1,967.72%
Earnings per share
-0.45
-0.28
-0.10
-0.20
Interest and investment income
-
-
-
-
Interest expense
-
-
-
-
Net interest expenses
-
-
-
-
Depreciation and amortization charges
-
-
-
-
EBITDA
-3.37M
-3.19M
-936.87K
-2.44M
Gain or loss from assets sale
-
-
-
-
Insiders
Politicians
Insider transactions
Insider transactions data is drawn from third-party sources.
Learn more
Insider
Position
Type
Date
Shares
Amount
first_page
keyboard_arrow_left
Page 1
keyboard_arrow_right
AI content may include mistakes.
Learn more
Help
Send feedback
Privacy
Terms
Disclaimer
Research
edit_square
New thread
notes_spark
Thread history
close
Collapse
expand_content
Expand
add
Add Tool
travel_explore
Deep Search
arrow_upward
Ask AI
search_spark
AI content may include mistakes.
Learn more
Help
Send feedback
Privacy
Terms
Disclaimer